Acadia pharmaceuticals inc. – product pipeline review


Published on

Published in: Business, News & Politics
  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Acadia pharmaceuticals inc. – product pipeline review

  1. 1. ACADIA Pharmaceuticals Inc. – Product Pipeline Review – Q2 2011ACADIA Pharmaceuticals Inc. – Product Pipeline Review – Q2 2011SummaryGlobal Market Direct’s pharmaceuticals report, “ACADIA Pharmaceuticals Inc. -Product Pipeline Review - Q2 2011” provides data on the ACADIA PharmaceuticalsInc.’s research and development focus. The report includes information on currentdevelopmental pipeline, complete with latest updates, and features on discontinuedand dormant projects.This report is built using data and information sourced from Global Markets Direct’sproprietary databases, ACADIA Pharmaceuticals Inc.’s corporate website, SECfilings, investor presentations and featured press releases, both from ACADIAPharmaceuticals Inc. and industry-specific third party sources, put together byGlobal Markets Direct’s team.Scope- ACADIA Pharmaceuticals Inc. - Brief ACADIA Pharmaceuticals Inc. overviewincluding business description, key information and facts, and its locations andsubsidiaries.- Review of current pipeline of ACADIA Pharmaceuticals Inc. human therapeuticdivision.- Overview of pipeline therapeutics across various therapy areas.- Coverage of current pipeline molecules in various stages of drug development,including the combination treatment modalities, across the globe.- Product profiles for late stage and clinical stage products of ACADIAPharmaceuticals Inc. with complete description of the product’s developmentalhistory, mechanism of action, therapeutic class, target and major milestones.- Recent updates of the ACADIA Pharmaceuticals Inc.’s pipeline in the last quarter.- Key discontinued and dormant projects.- Latest news and deals relating to the products.Browse All Pharmaceuticals Market Research ReportsReasons to buy- Evaluate ACADIA Pharmaceuticals Inc.’s strategic position with total access todetailed information on its product pipeline.- Assess the growth potential of ACADIA Pharmaceuticals Inc. in its therapy areasof focus.- Identify new drug targets and therapeutic classes in the ACADIA PharmaceuticalsInc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline inthose areas.- Exploit in-licensing opportunities by identifying windows of opportunity to fill
  2. 2. portfolio gaps.- Exploit collaboration and partnership opportunities with ACADIA PharmaceuticalsInc..- Avoid Intellectual Property Rights related issues.- Explore the dormant and discontinued projects of ACADIA Pharmaceuticals Inc.and identify potential opportunities in those areas.Table of ContentsTable of Contents 2List of Tables 4List of Figures 4ACADIA Pharmaceuticals Inc. Snapshot 5ACADIA Pharmaceuticals Inc. Overview 5Key Information 5Key Facts 5ACADIA Pharmaceuticals Inc. – Research and Development Overview 6Key Therapeutic Areas 6ACADIA Pharmaceuticals Inc. – Pipeline Review 8Pipeline Products by Stage of Development 8Pipeline Products – Monotherapy 9Pipeline Products – Combination Treatment Modalities 10ACADIA Pharmaceuticals Inc. – Pipeline Products Glance 11ACADIA Pharmaceuticals Inc. – Late Stage Pipeline 11Registration Filed Products/Combination Treatment Modalities 11Phase III Products/Combination Treatment Modalities 12ACADIA Pharmaceuticals Inc. Clinical Stage Pipeline Products 13Phase II Products/Combination Treatment Modalities 13Phase I Products/Combination Treatment Modalities 14ACADIA Pharmaceuticals Inc.–Early Stage Pipeline Products 15Pre-Clinical Products/Combination Treatment Modalities 15ACADIA Pharmaceuticals Inc. – Drug Profiles 16AM-831 16Product Description 16Mechanism of Action 16R&D Progress 16Pimavanserin 17Product Description 17Mechanism of Action 17R&D Progress 17Pimavanserin + Risperidone 18Product Description 18Mechanism of Action 18R&D Progress 18AC 262271 20Product Description 20Mechanism of Action 20R&D Progress 20
  3. 3. AC-260584 21Product Description 21Mechanism of Action 21R&D Progress 21ACP-105 22Product Description 22Mechanism of Action 22R&D Progress 22ACP-106 23Product Description 23Mechanism of Action 23R&D Progress 23AM-831 24Product Description 24Mechanism of Action 24R&D Progress 24ACADIA Pharmaceuticals Inc. – Pipeline Analysis 25ACADIA Pharmaceuticals Inc. – Pipeline Products by Therapeutic Class 25ACADIA Pharmaceuticals Inc. - Pipeline Products By Target 26ACADIA Pharmaceuticals Inc. – Pipeline Products by Route of Administration 27ACADIA Pharmaceuticals Inc. – Pipeline Products by Molecule Type 28ACADIA Pharmaceuticals Inc. – Recent Pipeline Updates 29ACADIA Pharmaceuticals Inc. - Dormant Projects 30ACADIA Pharmaceuticals Inc. – Company Statement 31ACADIA Pharmaceuticals Inc. – Locations And Subsidiaries 33Head Office 33Other Locations & Subsidiaries 33Financial Deals Landscape 34ACADIA Pharmaceuticals Inc., Deals Volume Summary, 2004 to YTD 2011 34ACADIA Pharmaceuticals Inc., Deals Summary By Region, 2004 to YTD 2011 35ACADIA Pharmaceuticals Inc., Deals Summary, 2004 to YTD 2011 36ACADIA Pharmaceuticals Inc. Detailed Deal Summary 37Venture Financing 37Abbey Pharmaceuticals Secures Seed Financing 37Equity Offering 38ACADIA Pharmaceuticals Completes Public Offering Of $102 Million 38ACADIA Pharmaceuticals Completes Public Offering Of $63 Million 40ACADIA Pharmaceuticals Completes Private Placement Of $36 Million 42ACADIA Pharmaceuticals Completes Initial Public Offering Of $35 Million 45ACADIA Pharmaceuticals Files Shelf Registration Statement For Public Offering Of$29 Million 47ACADIA Pharmaceuticals Expands Co-Development Agreement With Allergan 49ACADIA Pharmaceuticals Enters Into Agreement With Meiji Seika Kaisha 50ACADIA Pharmaceuticals Extends Co-Development Agreement With Allergan 51ACADIA Pharmaceuticals Extends Co-Development Agreement With Allergan 52ACADIA Pharmaceuticals Enters Into An Agreement With Sepracor 53Licensing Agreements 55
  4. 4. Biovail Enters Into Licensing Agreement With ACADIA Pharmaceuticals 55ACADIA Pharmaceuticals Enters Into Licensing Agreement With Ipsen 57ACADIA Pharmaceuticals Enters Into Licensing Agreement with AbbeyPharmaceuticals 58Appendix 59Methodology 59Coverage 59Secondary Research 59Primary Research 59Expert Panel Validation 60Contact Us 60Disclaimer 60About Us:ReportsnReports is an online library of over 100,000+ market research reports andin-depth market research studies & analysis of over 5000 micro markets. Weprovide 24/7 online and offline support to our customers. Get in touch with us foryour needs of market research reports.Follow us on Twitter: Facebook Page: Rambler road,Suite727,Dallas,TX75231Tel: + 1 888 391 5441E-mail: sales@reportsandreports.comhttp://www.reportsnreports.comVisit our Market Research Blog